Researchers have discovered subcellular signs of young-onset Parkinson’s disease that emerge before symptoms arise. Additionally, further testing has revealed a drug that may reverse these cellular abnormalities.
A recently published study has indicated that lithium, in doses of up to 400-times lower than what is currently being prescribed for mood disorders, could halt signs of advanced Alzheimer’s disease in rats.
PTC Therapeutics (NJ, USA) has announced positive topline results from part II of the FIREFISH trial, demonstrating that risdiplam was well tolerated in infants with Type 1 spinal muscular atrophy.
In this research article from the Journal of Comparative Effectiveness Research, the authors assess the real-world outcomes among patients with Duchenne muscular dystrophy receiving deflazacort or prednisone in real-world practice.
This review article from the journal Pain Management provides a summary of national and international evidence-based guidelines for common pain conditions to guide primary healthcare practitioners on recommended non-prescription analgesic treatments.
In this interview from the Video Journal of Biomedicine, Hannah Brown (Ipsos Healthcare, London, UK) discusses physician and patient treatment decision-making for relapsing–remitting multiple sclerosis.